CD274 and gastric cancer: Based on the results of cohort 1 in KEYNOTE-059, in September 2017, the U.S. FDA approved pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced GC after receiving 2 or more lines of treatment including fluoropyrimidine and platinum agents.